Platelet additive solution having a β-galactosidase inhibitor

Patent metadata

Field	Value
Publication number	US-9609861-B2
Application number	US-201314047689-A
Country	US
Kind code	B2
Filing date	Oct 7, 2013
Priority date	May 17, 2011
Publication date	Apr 4, 2017
Grant date	Apr 4, 2017

Abstract

The present invention relates to a platelet additive solution (PAS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof.

First claim

What is claimed is:

1. A method of storing platelets having a platelet surface, wherein sialic acid loss and galactose loss are reduced on the platelet surface of isolated platelets during storage, wherein the isolated platelets are obtained from one or more donors, the method comprises:
a. contacting the isolated platelets with a Platelet Additive Solution (PAS) that comprises:
i. from about 0.1 mM to about 100 mM of one or more β-galactosidase inhibitors and from about 0.1 mM to about 100 mM of one or more sialidase inhibitors, and optionally an amount of one or more glycan-modifying agents, or a combination thereof, wherein when platelets are stored, the sialic acid loss and galactose loss are caused by the presence of active endogenous sialidase and β-galactosidase, respectively, that have migrated to the platelet surface; and
ii. one or more of PAS components that includes a salt, a citrate source, a carbon source, an acetate source, or any combination thereof;

to thereby obtain a platelet composition, wherein cleavage by the endogenous sialidase and β-galactosidase of sialic acid or galactose, respectively, is reduced, as compared to isolated platelets not subjected to Step a); and wherein once the platelet composition is transfused into a recipient, circulation time of platelets is increased by at least 10% and platelet clearance of the platelets is reduced, as compared to circulation time and platelet clearance of platelets that have not been subjected to Step a).

2. The method of claim 1 , wherein the one or more sialidase inhibitors is selected from the group consisting of: fetuin; 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA); ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)-cyclohex-1-ene-1-carboxylate); (2R,3R,4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid; (4S,5R,6R)-5-acetamido-4-carbamimidamido-6-[(1R,2R)-3-hydroxy-2-methoxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid; (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid; a combination thereof and a pharmaceutically acceptable salt thereof.

3. The method of claim 2 , wherein the sialidase inhibitor is the sodium salt of 2,3-dehydro-2-deoxy-N-acetylneuraminic acid.

4. The method of claim 1 , wherein the one or more β-galactosidase inhibitors is selected from the group consisting of: 1-deoxygalactonojirimycin (DGJ); N-(n-butyl)deoxygalactonojirimycin; N-(n-nonyl)deoxygalactonojirimycin; 5-deoxy-L-arabinose; galactostatin bisulfate; 3′,4′,7-trihydroxyisoflavone; D-ribonolactone; N-octyl-4-epi-β-valienamine; phenylethyl β-D-thiogalactopyranoside; difluorotetrahydropyridothiazinone; 4-aminobenzyl 1-thio-β-D-galactopryranoside; a combination thereof; and a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the platelet composition is stored for a period of about 1 to about 21 days.

6. The method of claim 1 , wherein the platelet composition is stored at a temperature of between about 2° C. and about 25° C.

7. The method of claim 1 , further comprising cooling the platelet composition to a temperature below room temperature; storing the platelet composition for a period of time; and then rewarming the platelet composition back to room temperature.

8. The method of claim 1 , further comprising contacting the isolated platelets with the one or more β-galactosidase inhibitors and the one or more sialidase inhibitors, within a time period, wherein the time period is in a range between about 1 minute and about 8 hours.

9. The method of claim 1 , wherein the one or more PAS components include a citrate source present in an amount ranging from 2 mM to 20 mM, and wherein the citrate source is selected from the group consisting of monosodium citrate, disodium citrate, trisodium citrate, citric acid, and a combination thereof.

10. The method of claim 1 , wherein the one or more PAS components include a carbon source present in an amount ranging from 0.5 mM to 50 mM, and wherein the carbon source is selected from the group consisting of acetate, glucose, and sucrose.

11. The method of claim 1 , wherein the one or more PAS components include an acetate source present in an amount ranging from 10 mM to 50 mM, and wherein the acetate source is selected from the group consisting of sodium acetate, potassium acetate, magnesium acetate, and a combination thereof.

12. The method of claim 1 , wherein the one or more PAS components include a salt, and wherein the salt is selected from the group consisting of a sodium source, a chloride source, a potassium source, a magnesium source, a calcium source, and a combination thereof.

13. The method of claim 12 , wherein the salt includes a sodium source, and wherein the sodium source is selected from the group consisting of sodium chloride, sodium citrate, sodium acetate, sodium phosphate, and a combination thereof.

14. The method of claim 12 , wherein the salt includes a chloride source, and wherein the chloride source is selected from the group consisting of sodium chloride, magnesium chloride, potassium chloride, and a combination thereof.

15. The method of claim 12 , wherein the salt includes a potassium source, and wherein the potassium source is selected from the group consisting of potassium chloride, potassium citrate, potassium acetate, potassium phosphate, potassium sulfate, and a combination thereof.

16. The method of claim 12 , wherein the salt includes a magnesium source, and wherein the magnesium source is selected from the group consisting of magnesium chloride, magnesium citrate, magnesium sulfate, and a combination thereof.

17. The method of claim 12 , wherein the salt includes a calcium source, and wherein the calcium source is selected from the group consisting of calcium chloride, calcium acetate, calcium citrate, and a combination thereof.

18. The method of claim 1 , wherein the isolated platelets are mammalian platelets.

Assignees

• Velico Medical Inc
• Brigham & Womens Hospital Inc
• Velico Medical Inc

Inventors

• Liu Qiyong Peter
• Hoffmeister Karin
• Sackstein Robert

Classifications

• A61J1/10

  Bag-type containers · CPC title

• A01N1/0226 Primary

  Human Necessities · mapped topic

• A01N1/126 Primary

  Physiologically active agents, e.g. antioxidants or nutrients · CPC title